Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-REST: CBD for Short Term Insomnia
NCT05253417Phase 2Completed
- Sponsor
- Bod Science Limited
- Start
- May 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in Insomnia (3 arms), sponsored by Bod Science Limited. Primary endpoint: Insomnia Severity Index at 8 weeks. Started May 2022; status: completed.
02
Drugs
cannabidiol
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT05253417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253417.